Impact of obesity in the setting of high-dose chemotherapy
Open Access
- 28 May 2003
- journal article
- review article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 31 (11) , 961-966
- https://doi.org/10.1038/sj.bmt.1704052
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Effect of Obesity on the Leukocyte Nadir in Women Treated with Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil Dosed According to Body Surface AreaActa Oncologica, 2001
- Divergent trends in obesity and fat intake patterns: The american paradoxThe American Journal of Medicine, 1997
- Variability in Determination of Body Weight Used for Dosing Busulphan and Cyclophosphamide in Adult Patients: Results of an International SurveyLeukemia & Lymphoma, 1997
- Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.Journal of Clinical Oncology, 1996
- Obesity as an Adverse Prognostic Factor for Patients Receiving Adjuvant Chemotherapy for Breast CancerAnnals of Internal Medicine, 1994
- Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantationCancer Chemotherapy and Pharmacology, 1989
- Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distributionCancer Chemotherapy and Pharmacology, 1989
- Pharmacokinetic and metabolic studies of high-dose busulphan in adultsEuropean Journal of Clinical Pharmacology, 1989
- Doxorubicin clearance in the obese.Journal of Clinical Oncology, 1988
- Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patientsCancer Chemotherapy and Pharmacology, 1987